These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [Degradation of Azlocillin and Mezlocillin / I. Behaviour in biological material and buffer (author's transl)]. Gundert-Remy U; Weber E Arzneimittelforschung; 1981; 31(12):2041-4. PubMed ID: 6460506 [TBL] [Abstract][Full Text] [Related]
28. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients. Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683 [TBL] [Abstract][Full Text] [Related]
29. [Therapy with an antibiotic combination mezlocillin/oxacillin and clinical experience/First communication: Adults (author's transl)]. Chyský V; Hullmann R Arzneimittelforschung; 1979; 29(12a):2021-7. PubMed ID: 396931 [No Abstract] [Full Text] [Related]
30. Treatment of severe infections in patients with cancer. The role of new acyl-penicillins. Klastersky J Arch Intern Med; 1982 Oct; 142(11):1984-7. PubMed ID: 6215007 [TBL] [Abstract][Full Text] [Related]
31. Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination. Wildfeuer A; Schmalreck A; Räder K; Eibel G; Pfaff G Arzneimittelforschung; 1989 Jan; 39(1):94-100. PubMed ID: 2785802 [TBL] [Abstract][Full Text] [Related]
32. [An open comparative study of sulbactam/ampicillin vs mezlocillin in adult and pediatric patients. Efficacy and tolerability]. Chiodo F; Manfredi R; Zucchini A Minerva Med; 1991 Jun; 82(6):387-94. PubMed ID: 2067712 [TBL] [Abstract][Full Text] [Related]
33. [6R-[(R)-2-[3-[2-(p-Aminosulfonyl)anilino-4-hydroxy-5- pyrimidinyl]ureido]-2-(4-hydroxyphenyl)acetamido]-penicillanic acid, sodium salt (VX-VC 43), a new broad-spectrum beta-lactam antibiotic. In vitro and in vivo antibiotic activity]. Lechner U; Appel KR; Werner RG Arzneimittelforschung; 1985; 35(1A):351-5. PubMed ID: 3838677 [TBL] [Abstract][Full Text] [Related]
34. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis. Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901 [TBL] [Abstract][Full Text] [Related]
35. [Bacterial elimination and antibiotic concentration in the gall-bladder during biliary tract infections treated with mezlocillin (author's transl)]. Helm EB; Wurbs D; Gundlach H; Beyer B; Hagenmüller F; Stille W Dtsch Med Wochenschr; 1981 Aug; 106(35):1087-90. PubMed ID: 6455282 [TBL] [Abstract][Full Text] [Related]
36. [Microbiological care of ventilated intensive care patients. Feasibility of diagnosis and therapy of pulmonary infection]. Füssle R; Biscoping J; Zeiler D; Michaelis G; Sziegoleit A Anaesthesist; 1991 Sep; 40(9):491-6. PubMed ID: 1952044 [TBL] [Abstract][Full Text] [Related]
37. [Clinical evaluation of timentin in intensive care]. Gérard A; Dureux JB; Canton P; May T; Schmit JL Pathol Biol (Paris); 1986 May; 34(5):448-50. PubMed ID: 3534719 [TBL] [Abstract][Full Text] [Related]
38. [Bacteriologic and clinical analysis of nosocomial infections in patients from the intensive care unit]. Nikodemski T Ann Acad Med Stetin; 1999; 45():211-26. PubMed ID: 10909491 [TBL] [Abstract][Full Text] [Related]
39. Mezlocillin in serious surgical infections caused by carbenicillin-resistant bacteria. Lewandowski A; Orlowski T; Weuta H Infection; 1982; 10 Suppl 3():S125-7. PubMed ID: 6218098 [TBL] [Abstract][Full Text] [Related]
40. [Studies on the efficacy and tolerability of mezlocillin in female patients suffering from gynaecological-obstetric infections (author's transl)]. Weissenbacher ER; Tettenborn D Arzneimittelforschung; 1979; 29(12a):1999-2000. PubMed ID: 543911 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]